Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus

Kato, Hideo; Hagihara, Mao; Asai, Nobuhiro; Shibata, Yuichi; Koizumi, Yusuke; Yamagishi, Yuka; Mikamo, Hiroshige

doi:10.1016/j.jgar.2020.12.009

Cited by 47 publications

(35 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a recent study found a low overall rate of de-escalation in the setting of negative cultures, providing an opportunity to improve antibiotic use [74]. Possible empiric regimens recommended for MRSA pneumonia include vancomycin or linezolid [75]. Therapy for PSA includes piperacillin/tazobactam, cefepime, ceftazidime, aztreonam, meropenem, or imipenem.…”

Section: Pneumonia: Initial Empiric Therapy For Cap Hap Vapmentioning

confidence: 99%

Initial antimicrobial management of sepsis

et al. 2021

View full text Add to dashboard Cite

Sepsis is a common consequence of infection, associated with a mortality rate > 25%. Although community-acquired sepsis is more common, hospital-acquired infection is more lethal. The most common site of infection is the lung, followed by abdominal infection, catheter-associated blood steam infection and urinary tract infection. Gram-negative sepsis is more common than gram-positive infection, but sepsis can also be due to fungal and viral pathogens. To reduce mortality, it is necessary to give immediate, empiric, broad-spectrum therapy to those with severe sepsis and/or shock, but this approach can drive antimicrobial overuse and resistance and should be accompanied by a commitment to de-escalation and antimicrobial stewardship. Biomarkers such a procalcitonin can provide decision support for antibiotic use, and may identify patients with a low likelihood of infection, and in some settings, can guide duration of antibiotic therapy. Sepsis can involve drug-resistant pathogens, and this often necessitates consideration of newer antimicrobial agents.

show abstract

Section: Pneumonia: Initial Empiric Therapy For Cap Hap Vapmentioning

confidence: 99%

Initial antimicrobial management of sepsis

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Treatment Of Mrsa Hap/vapmentioning

confidence: 99%

“…Since the 2016 guidelines were published, a meta-analysis of seven randomized controlled trials and eight retrospective studies found robust evidence to support superior clinical outcomes in patients with MRSA pneumonia treated with linezolid. 43 Treatment of MRSA HAP/VAP Tedizolid is a high-potency oxazolidinone with activity against MRSA through inhibition of bacterial protein synthesis by binding to the bacterial 23S ribosomal RNA. 44 Tedizolid has lower risks of gastrointestinal side effects, less interactions with commonly used medications like antidepressants and less bone marrow toxicity compared to linezolid.…”

Section: Treatment Of Mrsa Hap/vapmentioning

confidence: 99%

Methicillin-Resistant Staphylococcus aureus Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia

Pickens

Wunderink

2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). MRSA pneumonia is associated with significant morbidity and mortality. Several virulence factors allow S. aureus to become an effective pathogen. The polysaccharide intracellular adhesin allows for the production of biofilms, some strains can produce capsular polysaccharides that protect against phagocytosis, microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) allow for colonization of epithelial surfaces, and S. aureus secretes several exotoxins that aid in tissue destruction. The α-hemolysin exotoxin secreted by S. aureus is one of the most important virulence factors for the bacteria. The diagnosis of MRSA pneumonia can be challenging; the infection may present as a mild respiratory infection or severe respiratory failure and septic shock. Many individuals are colonized with MRSA and thus a positive nasopharyngeal swab does not confirm infection in the lower respiratory tract. The management of MRSA pneumonia has evolved. Historically, vancomycin has been the primary antibiotic used to treat MRSA pneumonia. Over the past decade, prospective studies have shown that linezolid leads to higher rates of clinical cure. Monoclonal antibodies are being studied as potential therapeutic options. MRSA is an important cause of HAP/VAP; novel diagnostics may facilitate rapid diagnosis of this infection and the available literature should be used to make informed decisions on management.

show abstract

“…The most effective treatment against the multi-antibiotic-resistant MRSA is vancomycin or linezolid. Vancomycin is a glycopeptide antibiotic that is active against Gram-positive bacteria, however, it is ineffective against Gram-negative bacteria, mainly due to their outer membranes [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

MRSA as an indicator of infection control measures in Turaif General Hospital, Northern Area-Saudi Arabia

Taha

Al-Ruwaili

El-Masry

et al. 2022

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Saudi Arabia can be considered a hot spot for Methicillin-resistant Staphylococcus aureus (MRSA) infections with significant regional variations. As far as we know, this is the first study to evaluate the prevalence of MRSA in clinical samples obtained from Turaif general hospital (TGH), Northern Area-Saudi Arabia, and screening the resistance profile to the most regularly used antimicrobials as an indicator for evaluation of the implemented infection control measures. Methodology: Totally, 410 Samples were collected from patients in TGH with clinically suspected nosocomial infections. MRSA isolates were identified by the classical bacteriological, biochemical, and cefoxitin-based methods as recommended by the Clinical Laboratory Standard Institute. Confirmation of isolates and testing of their antimicrobial susceptibilities were performed by the automated Vitek 2 compact system. Results: Totally, 130 nosocomial isolates were detected. Staphylococcus aureus (29.23%) was the most frequently isolated Gram-positive pathogen. MRSA represented 39.47% of Staphylococcus aureus and 11.54% of all isolates. MRSA-causing surgical site infections were the most predominant type of MRSA nosocomial infections representing (25.00%). Recent antibiotic therapy, prolonged hospital stays, and indwelling devices were significant risk factors for the development of MRSA infections. Although all MRSA isolates were sensitive to vancomycin, teicoplanin, linezolid, Fosfomycin, and tigecycline, many isolates were resistant to other tested antimicrobials. Conclusions: Hospital administrators should strengthen the ideal use of antibiotics according to the local hospital policy to control the selective drug pressure on Staphylococcus aureus strains with minimizing exposure to the risk factors by implementing the proper infection control policies.

show abstract

Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus

Cited by 47 publications

References 32 publications

Initial antimicrobial management of sepsis

Initial antimicrobial management of sepsis

Methicillin-Resistant Staphylococcus aureus Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia

MRSA as an indicator of infection control measures in Turaif General Hospital, Northern Area-Saudi Arabia

Contact Info

Product

Resources

About